FDA approves Servier's ALL therapy acquired in Shire deal

FDA approved Asparlas calaspargase pegol-mknl (formerly SHP663) from Servier (Suresnes, France) to treat acute lymphoblastic leukemia in patients ages one month to 21 years old.

The pegylated L-asparaginase is approved as part of a multiagent chemotherapeutic regimen for ALL...